Topics:

Oncolytics kicks off reovirus trial

Oncolytics kicks off reovirus trial

Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.

 
Loading comments...
Please Wait 20 seconds or click here to close